Tuesday, April 26, 2022
- Analyzing whether a skinny label alone is enough to preclude induced infringement allegations
- Reviewing the implications of recent decisions for induced infringement
- Anticipating the impact of recent decisions on claim drafting and the availability of generic drugs
- Devising strategic considerations of label language for inducement infringement
- What considerations should patent owners keep in mind when labeling drugs?
- Reviewing the approval of generic drug labeling
- On what basis will FDA determine the scope of an appropriate carve-out?
- Must FDA review the patent to ensure the only information carved out is covered by the patent?
- Is the interpretation of the patent claims subject only to a jury’s interpretation?
- Assessing the flurry of follow-on cases in the courts
Event Details
Tuesday, April 26, 2022
In-Person and Livestream
New York, New York
Speakers
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
